Disclaimer: This article is for education and information only and is not financial advice, medical advice, or a recommendation to buy or sell any security. Compounded peptides discussed here are not FDA-approved; the FDA has not reviewed their safety or effectiveness.
This article is written in collaboration with Muse by Meta. Try it today: redeem my code 5PLTO0 in Settings within 48 hours of joining and we'll both get 1 billion Muse tokens.
What's in this report#
- What HHS actually did on October 30, and the six peptides it covers
- How we got here: the 2023 ban, the July vote against FDA staff advice, the AMA pushback
- The bypass question: what "enforcement discretion" legally is, and is not
- Can it last? The case for durable, the case for fragile
- The market math: $3 billion today, a $34 to $35 billion bet on tomorrow
- Who is set to benefit: Hims & Hers first, then the rest of the field
- What to watch next
What actually happened#↑ Contents
On October 28, 2026, Health Secretary Robert F. Kennedy Jr. signed a draft interim policy, published in the Federal Register on October 30, under which the federal government will not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides for individual patients holding a prescription. The six are BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon.
Read the conditions, because the conditions are the story. Each peptide is covered only in specific forms: BPC-157 by injection, mouth or skin; TB-500 and MOTS-c by injection; KPV by mouth or skin only; Semax as a nasal spray; Epitalon by injection in intermittent courses. One peptide per product, no blends. The raw ingredient must come from an FDA-registered manufacturer, with a certificate of analysis naming the original maker. Oral forms need documentation that the formulation is actually absorbed. Every product is labeled "This is a compounded drug product. Not for resale," packaged only with an FDA-cleared syringe, and serious side effects must be reported to the FDA's MedWatch system.
What the policy does not cover matters as much. The "research use only" vials sold online, the market this policy is designed to displace, remain outside it. The large 503B outsourcing facilities that supply hospitals are not covered. Neither are pens, blends, or the GLP-1 drugs that make up most of the money in peptides. And none of the six has been approved by the FDA, added to the official 503A bulks list, or reviewed for safety and effectiveness. HHS said so itself, in its own document.
How we got here#↑ Contents
In September 2023, the FDA placed BPC-157 and roughly eighteen other substances in Category 2 of its compounding framework, the tier for substances with significant safety risks. Compounding them effectively stopped. Demand did not. It moved to overseas websites selling vials labeled for laboratory research, a market with no prescriptions, no pharmacy standards and no adverse-event reporting at all.
In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend six of them for the 503A bulks list. BPC-157 passed 8 to 6 with one abstention. A seventh, emideltide, better known as DSIP, was rejected. The remarkable part: the FDA's own drug center, CDER, had recommended against all six, citing poorly defined chemistry, missing safety data and contamination risk. HHS's policy document answers that directly, saying the safety concerns CDER identified are, for several compounds, "inferential/mechanistic rather than based on observed harm." Two arms of the same department, reading the same evidence, landing in opposite places. That disagreement is now public record, and it is the fault line everything else runs along.
The medical establishment is pushing back. On November 9, the American Medical Association adopted a policy urging HHS and the FDA to "immediately rescind" any move that makes unapproved peptide compounding easier, and promised to press state pharmacy boards toward enforcement against compounders and telehealth sellers. The AMA's vote has no legal force, and the policy remains in place. Public comments on the policy closed November 13 with 289 received; HHS has not yet published a final version.
The bypass question#↑ Contents
So did HHS bypass the FDA? Formally, no rule was broken, because no rule was changed. That is precisely the point, and precisely the weakness.
The instrument is called enforcement discretion. It is not a law, not a regulation and not an approval. It is a written statement of present intent: we could enforce, and for now, under these conditions, we choose not to. The peptides remain off the bulks list. Compounding them remains, on the face of the statute, the production of unapproved drugs. What changed is the federal government's stated willingness to look away while licensed professionals do it under conditions the government wrote.
There is a legal paradox here that cuts in the policy's favor. Under a long-standing Supreme Court doctrine, an agency's decision not to enforce is presumptively unreviewable by courts. Opponents who want a judge to strike the policy down face a steep climb: you generally cannot sue an agency into enforcing a law. The AMA cannot litigate this away, and neither, most likely, can a safety group. The threat to the policy is not judicial. It is political and administrative: the same pen that signed it, or a successor's pen, can unsigned it in a day, with no rulemaking, no comment period and no vote.
HHS also built itself an exit ramp and said so out loud. The policy lasts until the FDA finishes formal rulemaking on each substance, and HHS can withdraw it earlier if safety or quality problems appear. One contaminated batch with a headline attached is the kind of event that ends policies like this.
Can it last? Both cases, honestly#↑ Contents
The case that this is durable runs like this. The pathway to permanence is not hypothetical; it is already moving. The advisory committee recommended inclusion. The interim policy explicitly bridges to FDA rulemaking on the bulks list, a process trade analysts estimate at eight to twelve months and that in practice can run longer. If the final rule adds these peptides to the list, the window closes into law, and what is now discretion becomes ordinary regulated compounding, the same legal footing as thousands of other compounded drugs. Politically, this is a signature initiative of the current health leadership, reviewed at the White House before it moved. It has an constituency now, too: within weeks, public companies were building product lines on it, which creates the kind of economic facts that make reversal costly.
The case that it is fragile runs like this. Discretion has ended quickly before, in this exact industry. When the FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, the compounding discretion that had built the compounded GLP-1 boom was wound down in sixty to ninety days. Companies that had treated a policy window as a permanent market learned the difference. The peptide window has no shortage clock, which helps, but it has something the GLP-1 window did not: an organized medical establishment on record against it, state boards that can be stricter than Washington, and an evidence base that even sympathetic executives describe as thin. Hims & Hers' own chief medical officer told CNBC, "We don't have all of this data that we're used to having with compounds like this."
Our read: treat the policy as a bridge, not a foundation. It is substantial enough to build a business on for two to three years, which in telehealth is enough time to build a brand, a subscriber base and clinical protocols that survive a rule change. It is not substantial enough to value as permanent law. The single most important document in this market over the next year is not a sales report. It is the FDA's proposed rule on the bulks list.
The market math#↑ Contents
Keep three numbers separate, because the coverage keeps blending them.
First, today. Analysts put the current market for these unapproved peptides, gray market included, at roughly $2.2 billion to $3.3 billion a year. That is the whole pond: research-chemical websites, med spas, clinics and the early telehealth entrants combined.
Second, the telehealth slice. Leerink Partners estimates a $2.2 billion market for telehealth companies from the first seven peptides reviewed, and its analyst Michael Cherny estimates Hims & Hers could capture about 20 percent of it, roughly $440 million of revenue.
Third, the bet. Needham estimates the addressable market for non-GLP-1 peptides at about $34 billion, with the US peptide market reaching about $35 billion within five years, up from roughly $3 billion of annual sales now. That number assumes permission holds, the category widens beyond six molecules, and mainstream consumers adopt what is today a biohacker market. It is a scenario, not a forecast of next year's sales. For scale, the entire approved peptide therapeutics market is about $50 billion in 2026, and nearly all of it is GLP-1 drugs from Eli Lilly and Novo Nordisk. The six peptides in this policy are, today, a rounding error next to that. The investment question is whether they stay one.
Demand signals are not the problem. Hims & Hers opened an early-access list in late October and drew more than 10,000 sign-ups in fifteen days, before it had a product to sell them.
Who is set to benefit#↑ Contents
Hims & Hers (NYSE: HIMS) moved first and moved loudest. This morning, November 18, it launched Peptides+, a new specialty built around clinician-guided protocols. Read the launch carefully, though, because it shows how a smart operator plays a discretionary window. The five treatments available today, sermorelin, NAD+, glutathione, vitamin B12 and L-carnitine, are not among the six policy peptides; they were already compoundable. The two headline names, BPC-157 and TB-500, "will follow, consistent with regulatory standards," with no date given. Hims is selling the category now and queuing the controversial molecules behind its clinical and legal review. It also owns the supply chain: it bought a peptide manufacturing facility in California in February 2025, a year and a half before the policy landed, and it pairs the treatments with Care+, its subscription layer of twice-yearly labs and round-the-clock provider messaging. Distribution, manufacturing and a subscription wrapper, assembled before the door opened. Among public companies, that is the strongest position in this market, which is why Barron's called Hims the biggest publicly traded beneficiary and why Needham's Ryan MacDonald carries a rare Buy with a $35 fair value on it.
The stock, for now, is telling a more cautious story. HIMS opened today at $17.89, ran to $18.20, and faded to about $17.40 by early afternoon, roughly flat on the day. The shares are down about 46 percent this year and about 38 percent in the last month, after a soft third quarter on November 9 (revenue of $890 million, a loss of $0.10 a share). The launch was telegraphed for weeks, the two biggest peptides are not yet on sale, and the revenue is back-ended and conditional on a policy that can be withdrawn. A rally built on this story has real ingredients. Today's tape says the market wants to see the BPC-157 launch and the final rule before it pays for them.
The rest of the field is moving quickly behind it. Noom, the weight-loss platform, is launching peptide products and argues that GLP-1 drugs normalized self-injection for millions of consumers. Enhanced began offering the six compounds shortly after the policy. Oddity, the Nasdaq-listed beauty group, is moving into peptide products for the anti-aging market. Superpower, a longevity startup, is taking pre-orders targeting late-November shipping. Behind all of them, the direct, mechanical beneficiaries are the 503A compounding pharmacies themselves: every prescription in this market must be filled by one, patient by patient.
And one intended loser. The policy's stated purpose is to pull demand out of the foreign research-chemical market, and HHS's own supplier data shows why the quality question is real: of the FDA bulk listings for these six peptides, a large share of the manufacturers that passed screening are registered in China. The policy requires an FDA-registered maker and a certificate of analysis, but it does not require American manufacture. The legal market will still run substantially on imported ingredients, now with paperwork.
What to watch next#↑ Contents
- The final version of the HHS policy, after the comment period that closed November 13. Changes to conditions matter more than changes to tone.
- The FDA's proposed rule on the 503A bulks list. Publication converts this from a window into a debate with an end date, one way or the other.
- Hims & Hers' BPC-157 and TB-500 launch timing, and its February 2027 earnings, the first print that could carry peptide revenue.
- State pharmacy boards. A few large states moving against compounding would fragment the national market the telehealth model depends on.
- The first serious adverse-event headline. In a discretionary regime, safety news is policy news.
Frequently Asked Questions#↑ Contents
Did the FDA approve BPC-157 and TB-500?#
No. None of the six peptides is FDA-approved, and the FDA has not reviewed their safety or effectiveness. HHS announced it will not take enforcement action against licensed pharmacies, federal facilities and physicians that compound them under specified conditions while formal rulemaking proceeds.
Which peptides does the policy cover?#
BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon, each only in specified forms and routes. A seventh peptide reviewed in July, emideltide (DSIP), was not included.
Is this a permanent change?#
No. It is an interim enforcement-discretion policy with no end date. It lasts until the FDA completes rulemaking on each substance, and HHS can withdraw it earlier if safety or quality problems appear.
How big is the market?#
Analysts estimate current sales of these unapproved peptides at roughly $2.2 billion to $3.3 billion a year. Leerink Partners estimates a $2.2 billion telehealth opportunity, and Needham estimates the broader non-GLP-1 peptide market could reach about $34 to $35 billion over five years if access holds and the category expands. These are analyst estimates, not audited figures.
Which companies benefit most?#
Hims & Hers is the most exposed public company: it launched its Peptides+ specialty on November 18, 2026, owns a California peptide manufacturing facility, and plans to add BPC-157 and TB-500. Noom, Enhanced, Oddity and Superpower are also moving into the category, and every sale must be filled by a licensed 503A compounding pharmacy.
Sources#↑ Contents
- Hims & Hers. "Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health." Business Wire, November 18, 2026.
- US Department of Health and Human Services. "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Federal Register, October 30, 2026 (FR Doc 2026-22192; docket HHS-OASH-2026-0496).
- Fortune. "HHS to Allow US Pharmacies to Sell Six FDA-Unapproved Peptides." November 16, 2026.
- BioProcess International. "HHS Greenlights Sale of Six Unapproved Peptides Despite FDA Guidance." November 4, 2026.
- Barron's. "Trump's FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?" (Needham and Leerink Partners market estimates.)
- CNBC, reporting on the Hims & Hers Peptides+ launch and comments by Chief Medical Officer Dr. Anant Vinjamoori, November 2026.
- Financial Times, reporting on telehealth and beauty company peptide launches and the Needham market estimate, November 2026.
- Market data: Finnhub quote snapshot for HIMS, November 18, 2026.